EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.

proton pump inhibitor

Drug-Drug Interactions to Avoid in Patients With GI Cancer

People with HER2-positive gastric cancer should not take proton pump inhibitors for heartburn while they are undergoing treatment, recent studies have found.

heartburn, HER2, proton pump inhibitor, risk, treatment

Share Post:

FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers

Biosimilar Trastuzumab Effective in Triplet Regimen for Gastric Cancer

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

1 day ago

“We are increasingly understanding that gastric cancer is more than one disease,” said John Marshall of Georgetown University's Lombardi Comprehensive Cancer Center in an interview with Cancer Network. ... See MoreSee Less

Zolbetuximab’s Impact on Gastric/GEJ Adenocarcinoma

www.cancernetwork.com

John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

4 days ago

Here’s how researchers at Cleveland Clinic built a predictive model to identify patients who may need to be routinely screened for stomach cancer. #artificialintelligence ... See MoreSee Less

Predictive model identifies at-risk patients who may need stomach cancer screening

medicalxpress.com

Cleveland Clinic developed a predictive model to identify patients at risk of developing gastric (stomach) cancer who may benefit from stomach cancer screening. The model is designed to identify who m...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

An analysis of 11,000 patient records by University of Colorado researchers revealed that an advanced surgery for gastric cancer that has spread to the liver often prolonged survival. ... See MoreSee Less

Surgery Can Offer Hope for Some Patients with Advanced Stomach Cancer

news.cuanschutz.edu

An analysis of nearly 11,000 patients points to a surgical approach that could “provide a survival advantage” for certain patients with stomach cancer.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

In a recent study, adding a novel HER2 antibody to a treatment of trastuzumab and chemotherapy prolonged progression-free survival in advanced gastric cancer. ... See MoreSee Less

Achieving PFS in Advanced Gastric Cancer With HLX02 Biosimilar, Chemotherapy

www.centerforbiosimilars.com

In a phase 2 study, the addition of HLX22, an anti-HER2 antibody, to HLX02 biosimilar and XELOX (oxaliplatin and capecitabine) chemotherapy extended progression-free survival (PFS) in untreated HER2-p...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Dr. Cindy M. Pabon of University of Miami’s Sylvester Comprehensive Cancer Center explains how recent phase 3 trial data improves targeted gastric cancer therapies. OncLive ... See MoreSee Less

Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers

www.onclive.com

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

X